RU2010146684A - Способ получения неиммуногенных гидрофобных белковых наночастиц и их применения - Google Patents

Способ получения неиммуногенных гидрофобных белковых наночастиц и их применения Download PDF

Info

Publication number
RU2010146684A
RU2010146684A RU2010146684/10A RU2010146684A RU2010146684A RU 2010146684 A RU2010146684 A RU 2010146684A RU 2010146684/10 A RU2010146684/10 A RU 2010146684/10A RU 2010146684 A RU2010146684 A RU 2010146684A RU 2010146684 A RU2010146684 A RU 2010146684A
Authority
RU
Russia
Prior art keywords
specified
nanoparticles
solution
aqueous phase
protein
Prior art date
Application number
RU2010146684/10A
Other languages
English (en)
Russian (ru)
Inventor
Оматану П. ПЕРУМАЛ (US)
Оматану П. ПЕРУМАЛ
Сатиш К. ПОДАРАЛЛА (US)
Сатиш К. ПОДАРАЛЛА
Рэдхей С. КАУШИК (US)
Рэдхей С. КАУШИК
Original Assignee
Саут Дакота Стейт Юниверсити (US)
Саут Дакота Стейт Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Саут Дакота Стейт Юниверсити (US), Саут Дакота Стейт Юниверсити filed Critical Саут Дакота Стейт Юниверсити (US)
Publication of RU2010146684A publication Critical patent/RU2010146684A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Medical Informatics (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2010146684/10A 2008-05-09 2009-05-11 Способ получения неиммуногенных гидрофобных белковых наночастиц и их применения RU2010146684A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12713408P 2008-05-09 2008-05-09
US61/127,134 2008-05-09

Publications (1)

Publication Number Publication Date
RU2010146684A true RU2010146684A (ru) 2012-06-20

Family

ID=41264904

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010146684/10A RU2010146684A (ru) 2008-05-09 2009-05-11 Способ получения неиммуногенных гидрофобных белковых наночастиц и их применения

Country Status (11)

Country Link
US (2) US8669225B2 (https=)
EP (1) EP2285825B1 (https=)
JP (2) JP5546532B2 (https=)
KR (1) KR101616771B1 (https=)
CN (1) CN102066399B (https=)
AU (1) AU2009244742B2 (https=)
BR (1) BRPI0908686B8 (https=)
CA (1) CA2723563C (https=)
IL (1) IL209155A (https=)
RU (1) RU2010146684A (https=)
WO (1) WO2009137112A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2170283B1 (en) 2007-06-22 2019-01-09 Board of Regents, The University of Texas System Formation of stable submicron peptide or protein particles by thin film freezing
US8697098B2 (en) 2011-02-25 2014-04-15 South Dakota State University Polymer conjugated protein micelles
US20140234420A1 (en) * 2008-05-09 2014-08-21 Omathanu P. Perumal Method of Treating Skin Disorders using Nanoscale Delivery Devices and Transdermal Enhancing Compositions
BRPI0908686B8 (pt) * 2008-05-09 2021-05-25 South Dakota State Univ método de produção de nanopartículas não-imunogênicas, nanopartícula não-imunogênica terapeuticamente ativa, composição terapêutica, uso de uma nanopartícula não-imunogênica e kit para a produção de nanopartículas não-imunogênicas
EP2376522A4 (en) 2008-11-16 2013-12-25 Univ Texas LOW VISCOSIS HIGHLY CONCENTRATED SUSPENSIONS
WO2012000757A1 (en) 2010-06-30 2012-01-05 Unilever Nv Particles comprising hydrophobic polymer and hydrophobic phenolic compound
PL2594140T3 (pl) * 2010-07-16 2019-09-30 Universidad De Navarra Nanocząstki do kapsułkowania związków, ich wytwarzanie i zastosowanie
CN102120823B (zh) * 2011-01-06 2016-08-03 鲁传华 水溶性玉米朊的合成及在药物制剂中的运用
BR112013021732B1 (pt) 2011-02-25 2021-11-30 South Dakota State University Micela estável e utilização da micela estável
EP2678007A4 (en) * 2011-02-25 2015-08-12 Univ South Dakota PROTEIN NANOTRIER FOR TOPICAL ADMINISTRATION
JP2014514275A (ja) * 2011-03-10 2014-06-19 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム タンパク質ナノ粒子分散系
JP6209517B2 (ja) * 2011-08-26 2017-10-04 ベコイ ナノメディシンズ リミテッドＶｅｃｏｙ Ｎａｎｏｍｅｄｉｃｉｎｅｓ Ｌｔｄ． 病原体を捕獲するための合成物および薬学的組成物
EP2625966A1 (en) 2012-02-13 2013-08-14 Bionanoplus, S.L. Nanoparticles comprising a vegetable hydrophobic protein and a water miscible non-volatile organic solvent and uses thereof
WO2014005299A1 (en) * 2012-07-04 2014-01-09 Empire Technology Development Llc Quantum dot-protein complexes, films, and methods of use
KR102045732B1 (ko) * 2012-12-28 2019-11-18 엘지디스플레이 주식회사 온도감응형 계면활성제를 이용한 수용성 나노입자의 제조방법
US20150150822A1 (en) * 2013-06-04 2015-06-04 South Dakota State University Novel core-shell nanoparticles for oral drug delivery
IL228528A (en) 2013-09-17 2015-01-29 Technion Res & Dev Foundation Potato-based nanoparticles
EP3204046A4 (en) * 2014-10-09 2018-08-08 Andreas Voigt Use of meso-and nanoporous material for surfactant trapping in nanoparticle suspensions
US11484505B2 (en) 2016-10-13 2022-11-01 Thomas Jefferson University Delivery compositions, and methods of making and using same
EP3639812A4 (en) 2017-06-02 2021-03-17 Teika Pharmaceutical Co., Ltd. SOLUBILIZED MICELLA CONSISTING OF A LOW SOLUBLE COMPONENT AND SOLUTION CONTAINING IT
TWI642685B (zh) * 2017-07-26 2018-12-01 中原大學 新穎胜肽及其應用
CN109432433A (zh) * 2018-10-30 2019-03-08 中国药科大学 一种纳米载体的制备方法和用途
CN109730976B (zh) * 2018-12-24 2020-06-09 华中科技大学 一种基于自由基氧化制备白蛋白纳米粒的方法
CN110251487B (zh) * 2019-08-01 2021-11-02 郑州大学 一种提高多西他赛载药量和口服生物利用度的醇溶蛋白纳米粒的制备方法及其应用
CN112121019B (zh) * 2020-09-23 2022-05-31 合肥工业大学 抗氧化型淀粉基糊精复合纳米颗粒及其制备方法与应用
CN115025054B (zh) * 2022-06-09 2023-12-22 四川普锐特药业有限公司 一种以乳铁蛋白为载体的纳米组合物的制备方法
CN116998582A (zh) * 2023-08-08 2023-11-07 扬州大学 一种高溶解度油料植物蛋白的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2236521A (en) 1937-08-12 1941-04-01 Zein Corp Of America Ink
US5330778A (en) 1988-09-19 1994-07-19 Opta Food Ingredients, Inc. Hydrophobic protein microparticles
WO1991006287A1 (en) * 1989-11-06 1991-05-16 Enzytech, Inc. Protein microspheres and methods of using them
US5254673A (en) 1991-12-26 1993-10-19 Opta Food Ingredients, Inc. Purification of zein from corn gluten meal
IE80468B1 (en) * 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
MY153295A (en) * 2004-09-29 2015-01-29 Nestec Sa Nanoparticulated whey proteins
US20070148251A1 (en) * 2005-12-22 2007-06-28 Hossainy Syed F A Nanoparticle releasing medical devices
CN101415395B (zh) * 2006-03-29 2012-02-08 富士胶片株式会社 酪蛋白纳米粒子
EP2054036B1 (en) * 2006-07-24 2019-12-18 Singh-Broemer and Company, Inc. Solid nanoparticle formulation of water insoluble pharmaceutical substances with reduced ostwald ripening
CN101485629B (zh) * 2008-01-16 2013-01-23 沈阳药科大学 一种给药系统及其制备方法
BRPI0908686B8 (pt) * 2008-05-09 2021-05-25 South Dakota State Univ método de produção de nanopartículas não-imunogênicas, nanopartícula não-imunogênica terapeuticamente ativa, composição terapêutica, uso de uma nanopartícula não-imunogênica e kit para a produção de nanopartículas não-imunogênicas
EP2678007A4 (en) * 2011-02-25 2015-08-12 Univ South Dakota PROTEIN NANOTRIER FOR TOPICAL ADMINISTRATION

Also Published As

Publication number Publication date
HK1158221A1 (en) 2012-07-13
CN102066399A (zh) 2011-05-18
EP2285825A4 (en) 2012-11-28
US9616021B2 (en) 2017-04-11
KR20110036704A (ko) 2011-04-08
EP2285825A1 (en) 2011-02-23
AU2009244742A1 (en) 2009-11-12
KR101616771B1 (ko) 2016-04-29
BRPI0908686B8 (pt) 2021-05-25
EP2285825B1 (en) 2020-07-15
JP5546532B2 (ja) 2014-07-09
IL209155A0 (en) 2011-01-31
CA2723563C (en) 2017-12-12
US8669225B2 (en) 2014-03-11
JP2011519932A (ja) 2011-07-14
BRPI0908686B1 (pt) 2020-09-29
US20140308351A1 (en) 2014-10-16
JP5851550B2 (ja) 2016-02-03
CN102066399B (zh) 2014-11-26
AU2009244742B2 (en) 2014-11-06
US20110091565A1 (en) 2011-04-21
IL209155A (en) 2016-07-31
CA2723563A1 (en) 2009-11-12
WO2009137112A1 (en) 2009-11-12
JP2014177474A (ja) 2014-09-25

Similar Documents

Publication Publication Date Title
RU2010146684A (ru) Способ получения неиммуногенных гидрофобных белковых наночастиц и их применения
Kim et al. Ceria‐based therapeutic antioxidants for biomedical applications
JP7290881B2 (ja) ＡｕＣ含有物質の使用
Vigani et al. Recent advances in the development of in situ gelling drug delivery systems for non-parenteral administration routes
JP2011519932A5 (https=)
CN111683653A (zh) 用于局部递送的方法和组合物
CN101330912A (zh) 一种多西他赛的药用组合物、制备方法及用途
US20040180094A1 (en) Activation agents on the surface of encapsulation vesicles
KR20190066040A (ko) Tie2 신호전달을 활성화시키기 위한 화합물 및 방법
WO2010069138A1 (zh) 一种谷维素组合物及其制备方法
AU2016358125A1 (en) Peptides with anti-angiogenic, anti-lymphangiogenic, and anti-edemic properties and nanoparticle formulations
TW202140036A (zh) 治療性多烯巨環內酯(polyene macrolide)之醫藥組合物及其使用方法
Pradhan et al. Nanomodulators that target Alzheimer’s disease: A review
Zhang et al. Cascade-targeting multifunctional nanochaperone remodels brain microenvironment for synergistic therapy of Alzheimer’s disease
CN113577016A (zh) 一种雷公藤甲素-金纳米颗粒/透明质酸复合水凝胶及其制备与应用
CN113413470A (zh) 肿瘤诊疗剂及其制备方法和应用
CN119235817B (zh) 含胍基结构的抗炎纳米载药体系及其制备方法和应用
Zhu et al. Intranasal administration of pullulan-based nanoparticles for enhanced delivery of adriamycin into the brain: in vitro and in vivo evaluation
CN110876757A (zh) 富勒烯结构在制备治疗动脉粥样硬化的药物中的应用
Demina et al. Development strategies and biopharmaceutical aspects of drug delivery systems
TWI616210B (zh) 經修飾微氣泡及其製備方法
CN111315399B (zh) 用于药物递送的葡萄糖敏感性组合物
AU2021385841C1 (en) Gold clusters, compositions, and methods for treatment of cerebral strokes
WO2010069140A1 (zh) 谷维素的药用产品及其制备方法
CN114081963A (zh) 一种提高活性肽生物利用度的纳米载体及其制备与应用

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20120512